

# **Physician's Orders RITUXIMAB, WEEKLY-**PEDIATRIC, OUTPATIENT, **INFUSION CENTER**

Page 1 of 5

Patient Name
DOB
MRN
Physician
FIN

		1 480 1 01 0			
Anticipated Ir	nfusion Date_		ICD 10 Code with De	scription	
Height	(cm	) Weight	(kg) Allergies		
Provider Sp	ecialty				
☐ Allergy/Imi	_	☐ Infectious □	Disease	□ OB/GYN	☐ Rheumatology
□ Cardiology	′	□ Internal Me	d/Family Practice	□ Other	□ Surgery
☐ Gastroente	erology	□ Nephrology	1	□ Otolaryngology	□ Urology
☐ Genetics		□ Neurology		☐ Pulmonary	☐ Wound Care
Site of Servi			(25)		
☐ SH Gerber			n Holton (GR)	☐ SH Pennock	☐ SH United Memorial
☐ SH Helen  Treatment Ir		☐ SH Ludingt	on	☐ SH Reed City	☐ SH Zeeland
☐ Conditionii		☐ Curative		☐ Mobilization	☐ Supportive
□ Control	19	□Maintenanc	Δ	□ Palliative	
		□ IVIainteriane	C	□ i alliative	
CARE 3, NON-O	NCOLOGY SI	UPPORTIVE CA	ARE, Non-Oncology S	PPORTIVE CARE 2, ONCO Supportive Care 2, Non-Onc EVANS, HEMATOLOGY,	cology Supportive Care 3
Cycles 1 – 4					Cycle length: 7 days
Day 1	ointment Requ	losts			Perform every 1 day x1
Аррс	_		ADDOINTMENT DEO	HEGT	
ONCBCN INFUSION APP Interval: Once			APPOINTMENT REQ		t
	Expecte	-	S+365, No date restric	Occurrences: 1 Treat	tment
Prov	ider Reminde	r			
	ONC P	ROVIDER REM	INDER 14		
	Interval	: Until discontin ents: Pretreatm symptoms	ued ent with acetaminoph	Occurrences: 1 Treat en and an antihistamine is r anaphylaxis, order "Peds	recommended. For
Trea	tment Parame	atere			
IIGa		FUNCTION PA	ANEI		
	Interval	: STAT	ood Central Line	Occurrences: 1 Treat	ment
Treatment Parameters  (a) C3 COMPLEMENT					
	Interval	: STAT	ood Central Line	Occurrences: 1 Trea	tment
	_	MPLEMENT			
	Interval	: STAT		Occurrences: 1 Trea	tment



Expected: S, Blood, Blood Central Line



# RITUXIMAB, WEEKLY PEDIATRIC, OUTPATIENT, INFUSION CENTER (CONTINUED)

Page 2 of 5

Patient Name	
DOB	
MRN	
Physician	

	Ī	rea	tme	nt F	Para	met	ters
--	---	-----	-----	------	------	-----	------

# © COMPLETE BLOOD COUNT (CBC) W/MANUAL DIFF

Interval: STAT Occurrences: 1 Treatment

Expected: S, Blood, Blood Central Line

#### **Treatment Parameters**

## **● CD20 BY FLOW CYTOMETRY**

Interval: STAT Occurrences: 1 Treatment

Expected: S, Blood, Blood Central Line

#### **Treatment Parameters**

#### **PROTEIN/CREAT RATIO, URINE**

Interval: STAT Occurrences: 1 Treatment

Expected: S, Blood, Blood Central Line

#### **Treatment Parameters**

# **©**RETICULOCYTE COUNT WITH RETICULOCYTE HEMOGLOBIN

Interval: STAT Occurrences: 1 Treatment

Expected: S, Blood, Blood Central Line

# Hydration

# sodium chloride 0.9% (NS) infusion

Dose: 65 mL/m²/hr Route: Intravenous PRN for dehydration

Start: S

Instructions:

Infuse until start of Rituximab.

#### Monoclonal Antibody

# ■ ACETAMINOPHEN (TYLENOL), CHOOSE ONE:

## acetaminophen (TYLENOL) tablet 15 mg/kg

Dose: 15 mg/kg Route: Oral Every 6 hours for 2 doses

Start: S

Instructions:

Administer 30 minutes prior to rituximab.

Recommended maximum single dose is 1000 mg.

No more than 5 doses from all sources in 24-hour period, not to exceed 4000 mg/day.

## acetaminophen (TYLENOL) 32 MG/ML suspension 15 mg/kg

Dose: 15 mg/kg Route: Oral Every 6 hours for 2 doses

Start: S

Instructions:

Administer 30 minutes prior to rituximab.

Recommended maximum single dose is 1000 mg.

No more than 5 doses from all sources in 24-hour period, not to exceed 4000 mg/day.





# RITUXIMAB, WEEKLY -PEDIATRIC, OUTPATIENT, INFUSION CENTER (CONTINUED)

DOB
MRN
Physician
FIN

Page 3 of 5

Monoc	Ional A	Antibody	۷

# ■ DIPHENHYDRAMINE (BENADRYL), CHOOSE ONE:

# OdiphenhydrAMINE (BENADRYL) injection 1 mg/kg

Dose: 1 mg/kg

Route: Intravenous

Every 6 hours for 2 doses

Patient Name

Start: S

Instructions:

Administer 30 minutes prior to rituximab.

Recommended maximum single dose is 50 mg.

## diphenhydrAMINE (BENADRYL) 12.5 MG/5ML elixir 1 mg/kg

Route: Oral

Dose: 1 mg/kg

Every 6 hours for 2 doses

Start: S

Instructions:

Administer 30 minutes prior to rituximab.

Recommended maximum single dose is 50 mg.

## diphenhydrAMINE (BENADRYL) capsule 1 mg/kg

Dose: 1 mg/kg

Route: Oral

Every 6 hours for 2 doses

Start: S

Instructions:

Administer 30 minutes prior to rituximab.

Recommended maximum single dose is 50 mg.

#### Monoclonal Antibody

#### methylPREDNISolone sodium succinate (SOLU-Medrol) injection 0.5 mg/kg

Dose: 0.5 mg/kg

Route: Intravenous

Once over 30 Minutes for 1 dose

Start: S

Instructions:

Administer 30 minutes prior to rituximab.

Recommended maximum single dose is 1000 mg.

Refer to IV Push policy for maximum IV Push dose and rate. Do not administer doses greater than 125 mg by IV Push.

#### Monoclonal Antibody

## **ONC PROVIDER REMINDER 25**

Interval: Until discontinued Occurrences: 1 Treatment

Comments: Ruxience is the Spectrum Health preferred product for rituximab. If insurance

dictates, alternate products are available under suggested protocol orders. Go to

actions, add orders and refer to the left side navigation pane.







# RITUXIMAB, WEEKLY -PEDIATRIC, OUTPATIENT, INFUSION CENTER (CONTINUED)

Page 4 of 5

Patient Name
DOB
MRN
Physician
FIN

PRO for s	ocional Antibody Select Either riTUXimab-pvvr (RUXIENCE) (PREFERRED FORMULARY DUCT) Or riTUXimab (RITUXAN) Or riTUXimab-abbs (TRUXIMA). Defer to insurance requirements pecific product covered. Proceed with administration based on coverage. If more than one is oved, will confirm with ordering provider.
	riTUXimab-pvvr (RUXIENCE) 1 mg/mL chemo infusion (subsequent infusion) 375 mg/m²
	Dose: 375 mg/m² Route: Intravenous Titrate for 1 dose Start: S
	Base Solution:
	☐ Sodium Chloride 0.9% ☐ Dextrose 5%
	□ Dexilose 5%
	Instructions: Hold hydration during infusion.
	INITIAL DOSE INFUSION RATE: Start IV infusion at mL/hour (0.5 mL/kg/hour,
	maximum rate 50 mL/hour) for 60 minutes. If patient tolerates without reaction, may escalate infusion rate by mL/hour (0.5 mL/kg/hour, maximum 50 mL/hour) every 30 minutes up to a maximum rate of mL/hour (4 mL/kg/hour, maximum 400 mL/hour).  SUBSEQUENT DOSE - STANDARD INFUSION RATE: Start IV infusion at mL/hour (1
	mL/kg/hour, maximum rate 100 mL/hour) for 60 minutes. If patient tolerates without reaction, may escalate infusion rate by mL/hour (1 mL/kg/hour, maximum 100 mL/hour) every 30 minutes up to a maximum of mL/hour (4 mL/kg/hour, maximum 400 mL/hour).
	OriTUXimab (RITUXAN) 1 mg/mL chemo infusion (subsequent infusion) 375 mg/m²  Dose: 375 mg/m²  Route: Intravenous  Titrate for 1 dose  Start: S
	Base Solution:  ☐ Sodium Chloride 0.9%  ☐ Dextrose 5%
	Instructions: Hold hydration during infusion.  INITIAL DOSE INFUSION RATE: Start IV infusion at mL/hour (0.5 mL/kg/hour, maximum rate 50 mL/hour) for 60 minutes. If patient tolerates without reaction, may escalate infusion rate by mL/hour (0.5 mL/kg/hour, maximum 50 mL/hour) every 30 minutes up to a maximum rate of mL/hour (4 mL/kg/hour, maximum 400 mL/hour).  SUBSEQUENT DOSE - STANDARD INFUSION RATE: Start IV infusion at mL/hour (1 mL/kg/hour, maximum rate 100 mL/hour) for 60 minutes. If patient tolerates without reaction, may escalate infusion rate by mL/hour (1 mL/kg/hour, maximum 100 mL/hour) every 30 minutes up to a maximum of mL/hour (4 mL/kg/hour, maximum 400 mL/hour).
	OriTUXimab-abbs (TRUXIMA) 1 mg/mL chemo infusion (subsequent infusion) 375 mg/m²  Dose: 375 mg/m²  Route: Intravenous  Titrate for 1 dose  Start: S
	Base Solution:  □ Sodium Chloride 0.9%  □ Dextrose 5%
	Instructions: Hold hydration during infusion.  INITIAL DOSE INFUSION RATE: Start IV infusion at mL/hour (0.5 mL/kg/hour, maximum rate 50 mL/hour) for 60 minutes. If patient tolerates without reaction, may escalate infusion rate by mL/hour (0.5 mL/kg/hour, maximum 50 mL/hour) every 30 minutes up to a maximum rate of mL/hour (4 mL/kg/hour, maximum 400 mL/hour).  SUBSEQUENT DOSE - STANDARD INFUSION RATE: Start IV infusion at mL/hour (1 mL/kg/hour, maximum rate 100 mL/hour) for 60 minutes. If patient tolerates without reaction, may escalate infusion rate by mL/hour (1 mL/kg/hour, maximum 100 mL/hour) every 30 minutes up to a maximum of mL/hour (4 mL/kg/hour, maximum 400 mL/hour).

# **RITUXIMAB, WEEKLY-**PEDIATRIC, OUTPATIENT, **INFUSION CENTER** (CONTINUED)

Page 5 of 5

Patient Name
DOB
MRN
Physician
FIN

#### **Nursing Orders**

# ONC NURSING COMMUNICATION 52

Interval: Until discontinued Occurrences: 1 Treatment

Comments: Rituximab

- Obtain heart rate, respiratory rate, blood pressure and pulse oximetry and assess for symptoms of anaphylaxis every 15 minutes during drug infusion through 30 minutes after drug completion.
- Notify pediatric oncologist, NP or PA-C and stop infusion immediately if patient has itching, hives, swelling, fever, rigors, dyspnea, cough, or bronchospasm.
- Notify pediatric oncologist, NP or PA-C if greater than 20% decrease in systolic or diastolic blood pressure.
- Verify that patient has diphenhydramine / Epi-pen available (as appropriate) for immediate home use. Advise patient that severe hypersensitivity or anaphylactic reactions may occur during and after infusion. Inform patients of signs and symptoms of anaphylaxis and hypersensitivity reactions, and importance of seeking medical care.

#### **Extravasation Guidelines**

## **ONC NURSING COMMUNICATION 10**

Interval: Until discontinued Occurrences: 1 Treatment

- Comments: 1. When an extravasation is suspected, stop the infusion. Disconnect the IV tubing, attach a syringe to the end of the catheter or butterfly and attempt to aspirate any residual drug from the site.
  - 2. Contact the attending provider. Use of pharmacologic antidotes remains controversial. The attending will determine if other pharmacologic treatments are appropriate.
  - 3. For more details about extravasation management refer to: https://members.childrensoncologygroup.org/ files/disc/Nursing/ExtravasationRefer ence.pdf (this link is available on the Springboard Report)
  - 4. Ensure patient/parent is educated about the extravasation and follow-up assessments.

#### **Extravasation Guidelines**

#### **ONC NURSING COMMUNICATION 53**

Interval: Until discontinued Occurrences: 1 Treatment

Comments: Rituximab is not an irritant or vesicant and extravasation does not require any local

care.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:				
	TIME	DATE	TIME	DATE	TIME	DATE	Pager #	
		Sign		R.N. Sign		Physician Print	Phys	ician

**EPIC VERSION DATE:**